Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Clinical evidence

VANGUARD

14 evidence topics · 4 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using monthly HAE attack rate as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized and included populations
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline sex distribution
Efficacy results
Published monthly attack rates and relative treatment effect
OutcomeReported value
Garadacimab: mean monthly attack rate“0·27”View highlighted excerpt for this quote
Placebo: mean monthly attack rate“2·01”View highlighted excerpt for this quote
Difference in means, percent“-87%”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Safety results
Nasopharyngitis adverse reactions
TreatmentParticipants, n (%)
Garadacimab, n=39“8 (21)”
Placebo, n=25“3 (12)”
Study limitations
Summary

Of 65 randomized participants, 64 were included in the reported comparison (39 receiving garadacimab and 25 receiving placebo) after one participant was randomized in error. Allocation was 3:2 across 28 centers, and the placebo group of 25 participants limits precision for between-group estimates and for uncommon adverse events. Eligibility required “two or more acute HAE attacks”. The primary endpoint, the number of HAE attacks per month, does not describe outcomes over longer treatment. No health-related quality of life result for this trial was identified. Garadacimab was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, run-in requirements, baseline attack rates, and observation periods can affect the reported attack rates.